Tamtam Try Tamtam free
Ipsen logo

Ipsen account plan

Oncology neuroscience rare diseases

At a glance

Ipsen is a Paris-based biopharmaceutical group in Oncology, Rare Disease and Neuroscience, with FY2025 sales of €3,675.9m and 5,535 employees.

Ipsen is a Paris-based global biopharmaceutical group focused on Specialty Care in Oncology, Rare Disease and Neuroscience, selling 9 drugs registered in over 100 countries with a direct commercial presence in 38 countries. Its main medicines are Somatuline, Cabometyx, Decapeptyl, Dysport, Iqirvo and Bylvay, marketed to specialists such as endocrinologists, oncologists and neurologists. FY2025 total sales were €3,675.9m (+10.9% at constant exchange rates), core operating income €1,294.1m (35.2% margin) and IFRS net profit €444.5m. It had 5,535 employees in 42 countries. Ipsen is publicly traded and family controlled, with Highrock and Beech Tree each holding 26.03% of the share capital at 31 December 2025.

Business units

Strategic priorities

Grow the portfolio beyond Somatuline
Accelerate key medicines such as Iqirvo, Bylvay, Cabometyx and Dysport; the portfolio excluding Somatuline grew 14.2% in 2025 and 24.8% in H1 2026.
External innovation
Build the pipeline mainly by sourcing assets externally in oncology, hematology and rare disease, with more than EUR 2 billion of pro forma firepower remaining after the Kartos and Memo deals.
Dysport in migraine launch
After positive Phase III results in episodic and chronic migraine, submissions are planned in H2 2026 and a launch expected in H2 2027, with DTC advertising and a significantly expanded field force.
Expand Iqirvo
The PBC peak sales estimate was raised to EUR 1 billion after ELSPIRE, and a Phase III in primary sclerosing cholangitis targets a population of 40,000 prevalent patients.
Next-generation toxins
Develop corabotase, a first-in-class recombinant neuroinhibitor, with aesthetic proof-of-concept data later in 2026, therapeutic data in two indications in 2027 and a first aesthetic Phase III readout in 2028.
Margin and 2030 ambition
Ipsen is "highly confident" of beating its 2023-2027 targets of at least 7% average annual sales growth and a 2027 core operating margin of at least 32%, and announced an enhanced ambition towards 2030 with a renewed strategy deployed in 2026.

Latest results

In H1 2026 total sales reached €2,190.2m, up 20.4% reported and 23.5% at constant exchange rates, with Oncology +15.6%, Rare Disease +108.0% and Neuroscience +16.6% at CER. Core operating income rose 28.8% to €844.9m, a core operating margin of 38.6%, and IFRS net profit was €402.6m (+20.0%). Free cash flow was €651.7m and net cash €1,004.9m at 30 June. FY2026 guidance was raised to sales growth greater than 20.0% at CER and a core operating margin greater than 37.0%, including dilution from the Memo and Kartos acquisitions. For 2027, management expects sales growth to continue but margin to be impacted by acquired R&D and the Dysport migraine launch.

Investments and deals

Kartos Therapeutics
Agreement to acquire Kartos (navtemadlin, Phase III in myelofibrosis) for $450m upfront plus up to $1.3bn in milestones, closing anticipated by end of Q3 2026.
Memo Therapeutics AG
Acquired in July 2026 for €200m upfront, adding potravitug, a Phase II antibody against BK polyomavirus in kidney transplant recipients.
ImCheck Therapeutics
Acquired for €350 million upfront plus milestones, closed 15 December 2025, adding ICT01 for first-line acute myeloid leukemia.
Licensing and pre-clinical deals
An ex-China licence for the SIM0613 ADC in December 2025 and seven pre-clinical assets added since January 2024, including three antibody-drug conjugates and three T cell engagers.
Manufacturing and financing
€66.9m manufacturing investment in 2025 with the Wrexham (UK) toxin facility being expanded; a €500 million 3.875% bond due 2032 and a €1,500m revolving credit facility were put in place in 2025.

Challenges and risks

Somatuline generics
Somatuline, the largest product at €1,135.4m in 2025, faces generic lanreotide entry, including an Amneal launch now expected more in Q4 2026.
Product concentration and competition
A few products make up the majority of sales; Dysport competes with Botox, Xeomin and other toxins, and Onivyde faces a new second-line competitor expected around September 2026.
R&D failures and withdrawals
Impairments of €257.6m after tax in 2025 (Tazverik and fidrisertib), Tazverik withdrawn in March 2026 after safety signals, and Bylvay's BOLD Phase III in biliary atresia failed.
U.S. pricing and tariffs
Market access and price pressure, and protectionist measures, tariffs and price-setting in the United States, are rated High risks.
Deal integration and IT
Licensing, acquisition and integration of deals, and IT systems and cyberattacks, are also among the risks rated High.

What leadership says

“Our excellent first-half performance demonstrates the strength of Ipsen's strategy, with all three therapeutic areas contributing to growth and the portfolio beyond Somatuline continuing to accelerate,”

David Loew, Chief Executive Officer · H1 2026 results press release, 30 July 2026

“Ipsen is delivering today accelerating growth from key medicines and expanding the pipeline to generate sustainable growth beyond 2027 with several potential blockbusters to come.”

David Loew, Chief Executive Officer · H1 2026 results conference call, 30 July 2026

“This will have a significant impact on the profitability.”

Aymeric Le Chatelier, Chief Financial Officer · On 2027 margin, H1 2026 results conference call, 30 July 2026

“We look forward to another year of accelerated growth as we continue on our transformation.”

David Loew, Chief Executive Officer · Full year 2025 results conference call, 12 February 2026

Where a supplier can help

Launch readiness for Dysport in migraine
The H2 2027 migraine launch with DTC advertising and a significantly expanded field force needs field force recruitment, medical affairs, market access and campaign support.
Clinical operations for acquired assets
Running Kartos's POIESIS Phase III with more than 600 patients across 250 sites and Memo's pivotal trial creates demand for CRO, site management and clinical data services.
Toxin manufacturing capacity
The Wrexham toxin facility expansion and reliance on external CMO partners point to suppliers of manufacturing equipment, CMO capacity and quality services.
Business development diligence
The external innovation model and remaining firepower make scientific due diligence, asset scouting and integration services relevant.
Cybersecurity and U.S. pricing analytics
IT and cyberattack risk and U.S. pricing pressure, both rated High, open room for security, gross-to-net and contracting analytics providers.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Ipsen?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Ipsen

What does Ipsen do?

Ipsen is a global biopharmaceutical company focused on Specialty Care in Oncology, Rare Disease and Neuroscience. Its medicines include Somatuline, Cabometyx, Decapeptyl, Dysport, Iqirvo and Bylvay.

What is Ipsen's revenue?

FY2025 total sales were €3,675.9m, up 10.9% at constant exchange rates. H1 2026 sales were €2,190.2m, and FY2026 guidance is sales growth greater than 20.0% at CER.

How many employees does Ipsen have?

Ipsen had 5,535 employees in 42 countries in 2025.

What is Ipsen's strategy?

Ipsen grows its Specialty Care portfolio through its global commercial presence while building its pipeline mainly through external innovation, with recent deals such as ImCheck, Memo and Kartos.

Who leads Ipsen?

David Loew has been CEO since July 2020, and Marc de Garidel chairs the Board. Aymeric Le Chatelier is CFO.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)